Background: Bilirubin-induced neurologic dysfunction (BIND) is a spectrum of preventable neurological sequelae in jaundiced newborns. Current total plasma bilirubin (B T ) concentration thresholds for phototherapy and/or exchange transfusion poorly predict BIND. Methods: The unbound (free) bilirubin (B f ) measured at these B T thresholds provides additional information about the risk for BIND. B f can be readily adapted to clinical use by determining B f population parameters at current B T thresholds. These parameters can be established using a plasma bilirubin binding panel (BBP) consisting of B T , B f , and two empiric constants, the maximum B T (B Tmax ) and the corresponding equilibrium association bilirubin constant (K). Results: B Tmax and K provide the variables needed to accurately estimate B f at B T < B Tmax to obtain B f at threshold B T in patient samples. Once B f population parameters are known, the BBP in a newborn can be used to identify poor bilirubin binding (higher B f at the threshold B T compared with the population) and increased risk of BIND. Conclusion: The BBP can also be used in jaundice screening to better identify the actual B T at which intervention would be prudent. The BBP is used with current B T thresholds to better identify the risk of BIND and whether and when to intervene.
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Clinicians have known for decades that newborns with hyperbilirubinemia and excessive bilirubin production or poor plasma bilirubin binding have an increased risk of bilirubin-induced neurologic dysfunction (BIND, kernicterus). [1] [2] [3] [4] [5] Both conditions increase brain bilirubin exposure, excessive production by increasing the bilirubin load, 4, [6] [7] [8] and poor plasma bilirubin binding by increasing the plasma levels of unbound (free) bilirubin (B f ), which is the bilirubin species moving freely between the vascular and extravascular spaces. [1] [2] [3] [9] [10] [11] [12] [13] [14] The elevated B f resulting from poor bilirubin binding forces a greater percentage of the accumulating bilirubin load (bilirubin produced -bilirubin excreted) into the extravascular space, exposing the brain to more bilirubin. 2, 5, 9, 10, 12, 14 The vascular bilirubin level and plasma total bilirubin concentration (B T ) will be correspondingly lower.
1, 3, 9, 10 If Andersen et al. 1 had measured B f in their premature newborns given daily sulfisoxazole or tetracycline, they would have found it to be about twice as high in those receiving sulfisoxazole versus those receiving tetracycline at any B T . 9 A greater load of bilirubin was therefore needed in the sulfisoxazole cohort to reach a given B T e.g., >12 mg/dL, 9 and the increased extravascular bilirubin lead to BIND occurring at B T well below that at which BIND would ordinarily occur in this population. 9, 15 Clearly, both poor bilirubin binding and the size of the bilirubin load were important factors in determining whether newborns receiving sulfisoxazole actually developed BIND. 3, 9, 14, 16 The axiom (not hypothesis) emanating from these elderly data is: both B T and B f contribute important information about the risk of BIND in hyperbilirubinemic newborns. B T reflects the size of the bilirubin load, and B f provides information about the percentage of the bilirubin load to which the brain is exposed at that B T . Bilirubin binding varies considerably in newborn and adult populations, making it impossible to gauge the B f from the magnitude of B T . 9, 10, [16] [17] [18] Currently, the hour-specific B T is used to assess the size of the bilirubin load, 19 and if coupled with B f measurements, clinicians would have even more information about the brain bilirubin exposure and the risk of BIND. 16, 20 Recent studies suggest the risk of BIND in term newborns with B T ≥ 30 mg/dL is about 10%. [21] [22] [23] Since there is considerable uncertainty as to when an exchange transfusion should be initiated in these newborns, [21] [22] [23] [24] [25] measuring bilirubin binding would be more helpful in identifying those needing the procedure.
Remarkably, despite the accumulating studies documenting the importance of B f in assessing the risk of BIND, [26] [27] [28] [29] [30] [31] [32] [33] [34] bilirubin binding has not found its way to the bedside except in Japan, 35 where B T and B f are used routinely and successfully for many years. [30] [31] [32] [33] Elsewhere, B T alone guides treatment with phototherapy and/or exchange transfusion using B T thresholds derived from ever-evolving clinical experience and expert consensus. [36] [37] [38] Unfortunately, this approach has resulted in excessive treatment, erratic clinician compliance, and considerable confusion without eliminating BIND. [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] Adding bilirubin binding to the clinical armamentarium is unlikely to resolve all these issues, but it will certainly offer some improvements for the current situation.
The clinical use of bilirubin binding has been effectively blocked because clinicians have been asking the wrong questions. B T was the original and only clinical laboratory (CL) test available for quantifying newborn jaundice, and it was several years before clinically suitable 'bilirubin binding tests' were developed. 5, [54] [55] [56] Clinicians then asked for proof that the 'binding tests' were superior to B T as predictors of BIND, which was not forthcoming. [57] [58] [59] The better question would have been 'How well does a jaundiced newborn who has reached a threshold B T bind bilirubin?' That question provides a natural pathway for bringing bilirubin binding to the bedside that is not dependent on problematic prospective studies comparing how well 'binding tests' and B T predict BIND.
In this Review, we argue that the key to bringing bilirubin binding safely and expeditiously to the bedside is to determine the population parameters for B f at current B T thresholds. The B f population data will serve as the reference metric 60 for quantifying how well a jaundiced newborn binds bilirubin as an additional factor in determining their risk of BIND, irrespective of whether the incidence of BIND is known. B f population parameters at threshold B T levels can be obtained by using a bilirubin binding panel (BBP) to measure bilirubin binding in about 400 patients from the population of interest. 20, 61 In our paradigm, both B T and B f are included in the BBP.
Two additional variables are needed in the BBP, the maximum B T (B Tmax ) and its corresponding equilibrium association constant (K). B Tmax is an empirical mass action upper limit of B T in a sample that is used with K to calculate B f at any B T < B Tmax (Equation 1). B Tmax and K are necessary to calculate B f at the threshold B T level since the B T of a sample will rarely be the threshold B T . It is important to note that B Tmax is not the plasma bilirubin binding capacity (BBC), i.e., the B T level at which ALL the plasma bilirubin binding sites are occupied. There are no tests for determining BBC although the term continues to be mistakenly applied to 'bilirubin binding test' endpoints. 17, 55 The BBP variables and other binding measurements are summarized in Table. 1.
The mass action chemical and mathematical relationships hematofluometry, not jematofluometry, could not get system to eliminate J and add H between the BBP components (B T , B f , B Tmax , and K) are shown below. 
A practical issue is how the BBP variables are obtained. B T has long been measured by the clinical laboratory (CL), and clinically suitable methods for measuring B f are available. 35, 54, 64 K is calculated from B T , B f , and B Tmax using Equation 1. B Tmax , however, is a 'new' variable introduced herein to avoid the long-standing misconception that albumin has only one bilirubin binding site that is clinically relevant. 17, 55, [64] [65] [66] [67] [68] The advantage of using the 'single-site' model is that the simplest mass action equations apply (e.g., Equation 1), and measured variables such as the concentrations of albumin or albumin-bound bilirubin that fluoresces 55, 68 Fig. 2 The change in B f as B T increases at an albumin concentration of 3.5 g/dL and assuming a single binding site with K hi = 1.71 dL/µg (100 L/µmol) or two binding sites with K hi = 1.71 dL/µg and K lo = 0.171 dL/µg (see Fig. 1 ). The individual points were calculated using standard binding equations. 62, 63 The lower affinity binding site significantly impacts the change in B f over the clinically relevant range of B T can be designated as the 'BBC' and substituted for B Tmax in Equation 1 (17, 55, (64) (65) (66) (67) (68) . Unfortunately, Equation 1 will not provide accurate estimates of B f at non-sample B T using the 'BBC' and corresponding K provided by these other methods.
Albumin has at least two bilirubin binding sites as shown in Fig. 1 .
69 The~10-fold difference in their affinity for bilirubin as quantified by their respective association constants, K hi > 10·K lo 62, 63, 69 is used to justify the assumption that only the high affinity site where bound bilirubin also fluoresces is clinically relevant. 18, 54, 67 Fig. 2 shows that both sites will significantly impact the change in B f as B T increases, invalidating the assumption that only the high affinity site is clinically relevant.
The inaccuracy of the 'single-site' model in predicting B f at nonsample B T is illustrated using bilirubin binding data from 72 newborns < 35 weeks' GA. 70 Table 2 contains a summary of the data before and after sample bilirubin enrichment. The concentration of binding sites where the bound bilirubin fluoresces (HMF 'BBC') was measured using hematofluorometry (HMF). 55 Table 3 shows the B f predicted using the CL albumin (A T ) or the HMF 'BBC' as B Tmax in Equation 1, with the corresponding K's calculated using the sample B f before bilirubin enrichment. As expected from Fig. 2 , both predicted higher average B f at the enriched B T compared with the measured B f , and B f could not be calculated in several samples because the enriched B T exceeded the B Tmax determined using the CL A T or the HMF test.
An empirical B Tmax that does not require assumptions about the actual bilirubin binding sites and will provide accurate estimates of B f at non-sample B T < B Tmax can be readily obtained from the B T and B f measured before and after sample bilirubin enrichment (B T1 , B f1 and B T2 , B f2 ) . (70) . Enriching samples with bilirubin to B T above the relevant B T thresholds and re-measuring B T and B f to obtain B Tmax and K for accurate estimates of B f at threshold B T < B Tmax will not require substantially more sample volume or time for testing. 17, 54, 71 
Once B f population parameters are available, the BBP can be used to help determine how best to treat a newborn that has reached or exceeded a B T threshold and also as a screening tool 72 to individualize the threshold B T as warranted. Table 4 shows current B T threshold guidelines for phototherapy and exchange transfusion in newborns <35 weeks' GA. Consider a clinician (armed with bilirubin binding) confronting a <28-week GA newborn that has reached the phototherapy B T threshold of 5 mg/dL. Assume the median B f for the population at B T = 5 mg/dL is 0.30 µg/dL with the 25 th percentile 0.15 µg/dL and the 75 th percentile 0.45 µg/dL. If the newborn's B f is >0.30 µg/dL phototherapy is indicated and if it is >0.45 µg/dL there is considerable cause for concern as the binding is 'poor' relative to the population. If the median B f for the population at the threshold exchange transfusion B T were 1.0 µg/ dL, 34 B Tmax and K from the newborn's BBP and the B f of 1.0 µg/dL can be used in Equation 1 to calculate the actual B T at which the B f would reach 1.0 µg/dL. This approach provides considerably more information about the risk of BIND even though the actual risk is unknown and individualizes care.
It is important to note that B f varies with the local environment, temperature, sample dilution, GA, illness, and the presence of endogenous or exogenous ligands competing for bilirubin The instrument readout is 'BBC' referring to the maximum concentration of bound bilirubin that fluoresces, not the plasma BBC Table 3 . B f calculated at the enriched B T for the 110 samples in Table 2 binding sites. 9, 10, 14, 17, [73] [74] [75] [76] [77] [78] [79] [80] Therefore, comparisons of outcome and B f across institutions will require measuring B f under standard conditions. B Tmax and K, although empirical with respect to specific bilirubin binding sites, are critical binding components required for reliable determination of B f at relevant threshold B T . The use of the BBP will individualize care and as patient data accumulates may help better clarify the relationships between neonatal bilirubin exposure and BIND. In the meantime, the BBP can provide additional guidance for the clinicians caring for jaundiced newborns.
SUMMARY BIND is a spectrum of neurological disorders affecting jaundiced newborns and unpredictably related to the magnitude of B T . The BBP (B T , B f , B Tmax , and K) can provide important additional information about the risk of developing BIND and the need for treatment at threshold B T , irrespective of whether the actual incidence of BIND at or above that B T is known. The BBP components can be obtained using minimal modification of well described, clinically suitable methods, and when configured as described in this Review, provide accurate estimations of B f at B T < B Tmax . The BBP can be used to establish B f population parameters at current threshold B T that are the metric for quantifying how well a newborn binds bilirubin, which provides important additional information the risk of BIND and need for intervention The BBP is useful as a screening tool as well as for determining the urgency of treatment in newborns reaching or exceeding threshold B T . This approach to the clinical of use of bilirubin binding augments current clinical practice within the context of established B T thresholds and helps individualize care.
